# Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies

Source: https://onco.cc/trials/nct03539822/  
OnCo record `nct03539822` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of cabozantinib, durvalumab and tremelimumab in colorectal cancer, run by Anwaar Saeed, now recruiting.

## Summary

Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies is a phase 1/2, interventional study registered as NCT03539822 by Anwaar Saeed, with a registry enrolment figure of 117 participants, started 2018-10-22 and due to reach its primary completion in 2028-06-30. Interventions recorded: Cabozantinib; Durvalumab; Tremelimumab. Conditions listed: Gastric Cancer; Esophageal Adenocarcinoma; Hepatocellular Carcinoma; Colorectal Cancer. Primary outcome: Phase I- Maximum Tolerated Dose (MTD); Phase II- Overall Response Rate (ORR). Colorectal eligibility wording from the registry: "* Colorectal adenocarcinoma (CRC)". Sites: United States. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Also known as: CAMILLA
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT03539822
- Phase: 1/2
- Setting: A Phase I/II Trial of Cabozantinib in Combination With Durvalumab (MEDI4736) With or Without Tremelimumab in Patients With Advanced Gastroesophageal Cancer and Other Gastrointestinal (GI) Malignancies (CAMILLA)
- Sponsor: Anwaar Saeed
- Enrolled: 117

## Sources

- ClinicalTrials.gov NCT03539822: https://clinicaltrials.gov/study/NCT03539822

## Connected records

- cancers: [Colon cancer (adenocarcinoma of the colon)](https://onco.cc/cancers/colon-cancer/), [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- drugs: [Cabozantinib](https://onco.cc/drugs/cabozantinib/), [Durvalumab](https://onco.cc/drugs/durvalumab/), [Tremelimumab](https://onco.cc/drugs/tremelimumab/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/), [Exelixis](https://onco.cc/companies/exelixis/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct03539822.json